LQDA — Liquidia Corp

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1819576 ·
Last close
$56.73
Market Cap
$5.11B
52W High
$93.61
52W Low
$22.31
ADV30
4,133,583
Next earnings
2026-11-10
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 225,300,000 210,523,000 126,230,000 -236,328,000 682,942,000 396,091,000 708,376,000
Jun 2026 171,679,000 160,129,000 85,517,000 74,722,000 521,918,000 284,181,000 326,804,000
Mar 2026 132,865,000 121,013,000 61,504,000 52,862,000 401,533,000 222,786,000 292,954,000
Dec 2025 92,021,000 84,966,000 19,787,000 14,555,000 327,934,000 190,680,000 283,186,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$324,156,000
Investing CF
$-36,005,000
Financing CF
$-49,556,000
CapEx
$-36,005,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.23
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-735,057,000
Inventory
$36,174,000
Receivables
$116,749,000
ST Investments
—
EBIT TTM
$-90,796,000
Pretax Income TTM
$-113,365,000
Interest Exp TTM
$22,569,000
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$621,865,024
EBITDA
$294,200,000
Free Cash Flow
$535,596,992
Enterprise Value
$4,945,677,824
Total Cash
$396,091,008
Total Debt
$168,758,000
Shares Out
90,106,442
Trailing EPS
$-1.05
Book Value
$-0.28
ROE
131.8%
ROA
38.2%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 158,320,000 -51,376,000 -68,924,000 327,934,000 283,186,000 44,748,000 -35,686,000
Dec 2024 13,996,000 -121,294,000 -128,291,000 230,313,000 150,935,000 79,378,000 -93,422,000
Dec 2023 17,488,000 -73,384,000 -78,502,000 118,332,000 71,039,000 47,293,000 -41,564,000
Dec 2022 15,935,000 -38,770,000 -41,015,000 129,198,000 38,776,000 90,422,000 -28,588,000

TTM Snapshot

Revenues TTM
$450,907,000
NetIncome TTM
$138,606,000
OpCashFlow TTM
—
Assets (Latest)
$521,918,000
Forward EPS
$3.44

Max Pain — expiry 2026-12-18

max pain strike: $45.00 · spot: $56.40 · call oi: 13,441 · put oi: 2,753
Expected Move to 2026-12-18: ±$8.30 (14.72%) — implied range $48.10 – $64.70 · ATM straddle on $57.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
PTCT PTC THERAPEUTICS, INC. $5.04B $60.36 —
MANE Veradermics, Inc $5.30B $125.64 —
TVTX Travere Therapeutics, Inc. $4.91B $51.10 —
DNTH Dianthus Therapeutics, Inc. /DE/ $4.90B $86.98 —
ERAS Erasca, Inc. $4.87B $13.89 —

News headlines (Yahoo Finance, 1h cache)

Will Revenue Growth And Wider Losses Change Liquidia (LQDA) Stock Narrative
2026-11-18 01:11 · Yahoo
LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales
2026-11-11 16:38 · Yahoo
Nvidia downgraded, Mercury Systems upgraded: Wall Street's top analyst calls
2026-11-11 14:45 · Yahoo
LQDA Q3 Earnings Call Highlights Growth and Post-Settlement Outlook
2026-11-11 14:00 · Yahoo
Liquidia (LQDA) Q3 2026 Earnings Call Transcript
2026-11-10 19:00 · Yahoo
Liquidia Q3 Earnings Call Highlights
2026-11-10 18:15 · Yahoo
Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
2026-11-10 13:00 · Yahoo
Liquidia Corporation (LQDA) Q3 Earnings and Revenues Beat Estimates
2026-11-10 11:40 · Yahoo
Liquidia Corporation Reports Third Quarter 2026 Financial Results
2026-11-10 11:30 · Yahoo
Liquidia (LQDA) Stock Looks Rich Relative To Its Earnings Power
2026-11-10 03:11 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.